MAOA and pachyonychia congenita: Overall, it has been established that high expression levels of MAOA correlate with worse prognosis and that MAOA promotes growth, progression, metastasis and therapy resistance in PC, which provides a strong clinically relevant rationale for targeting MAOA and repurposing MAOA inhibitors for treating PC.